Over 75% of the public responded that high-priced innovative new drugs, or so-called ‘one-shot treatments,’ should be covered by the National Health Insurance. As to the maximum price the public was willing to pay for such treatments, the average price was ₩13.52 million, and the most amount of respondents - 33.3% - agreed to the price.

The Korean Organization for Rare Disease recently announced the results of a public survey on reimbursing innovative new drugs, which was commissioned to Gallup and sponsored by National Assembly Health and Welfare Committee member Sun-woo Kang of the Democratic Party of Korea. The survey was conducted online on 1,018 adults between the age of 19 to 65.